Has Roger Amerian received payments from drug or device companies?

Yes. Drug and device makers reported $2,655 in general payments to Roger Amerian across 168 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roger Amerian did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roger Amerian come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roger Amerian

Pulmonary Disease · West Hills, CANPI 1033105614

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,495 and has fallen 98.9% since, to $16 in 2023.

$2,655in general payments, 2019–2025

Across 168 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$586
GSK$565
Boehringer Ingelheim$509
Grifols USA, LLC$234
Actelion Pharmaceuticals US, Inc.$227
EPI Health, LLC$178
plus $356 from 7 others

What the payments were for

Food & beverage$2,653100%
Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	27	$586
GSK	49	$565
Boehringer Ingelheim	35	$509
Grifols USA, LLC	18	$234
Actelion Pharmaceuticals US, Inc.	12	$227
EPI Health, LLC	1	$178
Advanced Respiratory, Inc	6	$136
Sunovion Pharmaceuticals Inc.	14	$103
AbbVie	2	$41
Regeneron Healthcare Solutions, Inc.	1	$34
Sanofi	1	$24
Electromed, Inc.	1	$16
United Therapeutics Corporation	1	$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,655 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Furosemide	13	$62

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in West Hills

Samuel LouieSacramento$2.8M
Shyamsunder SubramanianTracy$1.5M
Toby MaherLos Angeles$1.3M
Rajkumar DasguptaPasadena$930K
Hoang leFountain Valley$814K
Kevin FussellEncinitas$788K
Revati ShreeniwasStanford$726K
David PhamWestminster$571K
Vijay BalasubramanianFresno$529K
Victor TapsonLos Angeles$514K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →